Advertisement

Heart Failure with Preserved Ejection Fraction

  • James Gallagher
  • Michael Fong
Chapter

In 2007, it was estimated that the United States would spend $33.2 billion dollars on both the direct and indirect costs of heart failure (HF). In 2004, hospital discharges for HF numbered 1,099,000 up from 399,000, twenty-five years prior. In 2002, total-mention mortality for HF was 296,700 people. 1 The proportion of patients with heart failure with preserved ejection fraction (HFPEF) is increasing over time, and unlike those with reduced systolic function, survival is not appreciably improving. 2 In addition, despite the growing prevalence, few well-designed, large clinical trials exist. 3, 4 This chapter is intended to define heart failure in the setting of preserved ejection fraction, report the current understanding of causation, identify methods to assess this form of heart failure, and discuss current strategies for treatment.

Keywords

Diastolic Dysfunction Heart Failure With Preserve Ejection Fraction Myosin Head Diastolic Filling Diastolic Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Rosamond, W., et al, Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2007. 115(5): pp. e69–e171.PubMedCrossRefGoogle Scholar
  2. 2.
    Owan, T.E., et al, Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med, 2006. 355(3): pp. 251–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Haney, S., D. Sur, and Z. Xu, Diastolic heart failure: a review and primary care perspective. J Am Board Fam Pract, 2005. 18(3): pp. 189–98.PubMedCrossRefGoogle Scholar
  4. 4.
    Banerjee, P., et al, Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol, 2002. 39(1): pp. 138–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Zile, M.R., Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol, 2003. 41(9): pp. 1519–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Burkhoff, D., M.S. Maurer, and M. Packer, Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation, 2003. 107(5): pp. 656–8.PubMedCrossRefGoogle Scholar
  7. 7.
    McKee, P.A., et al, The natural history of congestive heart failure: the Framingham study. N Engl J Med, 1971. 285(26): pp. 1441–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J, 1995. 16(6): pp. 741–51.Google Scholar
  9. 9.
    How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J, 1998. 19(7): pp. 990–1003.Google Scholar
  10. 10.
    Vasan, R.S. and D. Levy, Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation, 2000. 101(17): pp. 2118–21.PubMedGoogle Scholar
  11. 11.
    Zile, M.R., et al, Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation, 2001. 104(7): pp. 779–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Caruana, L., et al, Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study. BMJ, 2000. 321(7255): pp. 215–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Hunt, S.A., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005. 46(6): pp. e1–e82.PubMedCrossRefGoogle Scholar
  14. 14.
    Baicu, C.F., et al, Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation, 2005. 111(18): pp. 2306–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Redfield, M.M., Heart failure-an epidemic of uncertain proportions. N Engl J Med, 2002. 347(18): pp. 1442–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Roger, V.L., et al, Trends in heart failure incidence and survival in a community-based population. JAMA, 2004. 292(3): pp. 344–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Pernenkil, R., et al, Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol, 1997. 79(2): pp. 216–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Vasan, R.S., et al, Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol, 1999. 33(7): pp. 1948–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Hogg, K., K. Swedberg, and J. McMurray, Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol, 2004. 43(3): pp. 317–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Smith, G.L., et al, Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol, 2003. 41(9): pp. 1510–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Solomon, S.D., et al, Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation, 2005. 112(24): pp. 3738–44.PubMedCrossRefGoogle Scholar
  22. 22.
    Yusuf, S., et al, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003. 362(9386): pp. 777–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Zipes, D.P. and E. Braunwald, Braunwald's heart disease: a textbook of cardiovascular medicine. 7th ed. 2005, Philadelphia, Pa.: Elsevier Saunders.Google Scholar
  24. 24.
    Lam, C.S., et al, Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation, 2007. 115(15): pp. 1982–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Aurigemma, G.P., et al, Reduced left ventricular systolic pump performance and depressed myocardial contractile function in patients > 65 years of age with normal ejection fraction and a high relative wall thickness. Am J Cardiol, 1995. 76(10): pp. 702–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Kitzman, D.W., et al, Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol, 1991. 17(5): pp. 1065–72.PubMedCrossRefGoogle Scholar
  27. 27.
    Zile, M.R. and D.L. Brutsaert, New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation, 2002. 105(12): pp. 1503–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Borbely, A., et al, Cardiomyocyte stiffness in diastolic heart failure. Circulation, 2005. 111(6): pp. 774–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Ahmed, S.H., et al, Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation, 2006. 113(17): pp. 2089–96.PubMedCrossRefGoogle Scholar
  30. 30.
    Diez, J., et al, Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation, 2002. 105(21): pp. 2512–7.PubMedCrossRefGoogle Scholar
  31. 31.
    van Heerebeek, L., et al, Myocardial structure and function differ in systolic and diastolic heart failure. Circulation, 2006. 113(16): pp. 1966–73.PubMedCrossRefGoogle Scholar
  32. 32.
    Neubauer, S., The failing heart-an engine out of fuel. N Engl J Med, 2007. 356(11): pp. 1140–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Maurer, M.S., et al, Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail, 2005. 11(3): pp. 177–87.PubMedCrossRefGoogle Scholar
  34. 34.
    Otto, C.M., Textbook of clinical echocardiography. 3rd ed. 2004, Philadelphia, Pa.: Elsevier Saunders. xiii, 541 p.Google Scholar
  35. 35.
    Aurigemma, G.P. and W.H. Gaasch, Clinical practice. Diastolic heart failure. N Engl J Med, 2004. 351(11): pp. 1097–105.PubMedCrossRefGoogle Scholar
  36. 36.
    Warner, J.G., Jr., et al, Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol, 1999. 33(6): pp. 1567–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Setaro, J.F., et al, Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol, 1990. 66(12): pp. 981–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Kostis, J.B., et al, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA, 1997. 278(3): pp. 212–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Aronow, W.S. and I. Kronzon, Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol, 1993. 71(7): pp. 602–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Aronow, W.S., C. Ahn, and I. Kronzon, Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol, 1997. 80(2): pp. 207–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Pitt, B., et al, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999. 341(10): pp. 709–17.PubMedCrossRefGoogle Scholar
  42. 42.
    Bernal, J., S.R. Pitta, and D. Thatai, Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am J Cardiovasc Drugs, 2006. 6(6): pp. 373–81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2009

Authors and Affiliations

  • James Gallagher
    • 1
  • Michael Fong
    • 2
  1. 1.Department of Medicine, Cardiology DivisionUniversityof RochesterRochesterUSA
  2. 2.Department of Medicine, Cardiology DivisionHeart Failure and Transplantation Program, School of Medicine and Dentistry University of RochesterRochesterUSA

Personalised recommendations